Molecular Profiling, Other
Molecular Analysis for Therapy Choice – Phase 2 Study of BVD-523 (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, firstname.lastname@example.org or 406-969-6067, for the consent & for any questions.